324 related articles for article (PubMed ID: 34864823)
1. Differentiation therapy for myeloid malignancies: beyond cytotoxicity.
Stubbins RJ; Karsan A
Blood Cancer J; 2021 Dec; 11(12):193. PubMed ID: 34864823
[TBL] [Abstract][Full Text] [Related]
2. More is better: combination therapies for myelodysplastic syndromes.
Ornstein MC; Mukherjee S; Sekeres MA
Best Pract Res Clin Haematol; 2015 Mar; 28(1):22-31. PubMed ID: 25659727
[TBL] [Abstract][Full Text] [Related]
3. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Stahl M; Gore SD; Vey N; Prebet T
Expert Opin Investig Drugs; 2016; 25(3):307-17. PubMed ID: 26807602
[TBL] [Abstract][Full Text] [Related]
4. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.
Larsson CA; Cote G; Quintás-Cardama A
Mol Cancer Res; 2013 Aug; 11(8):815-27. PubMed ID: 23645565
[TBL] [Abstract][Full Text] [Related]
5. Targeting Immune Signaling Pathways in Clonal Hematopoiesis.
Azrakhsh NA; Mensah-Glanowska P; Sand K; Kittang AO
Curr Med Chem; 2019; 26(28):5262-5277. PubMed ID: 30907306
[TBL] [Abstract][Full Text] [Related]
6. [Biological and clinical significance of TP53 mutations in myelodysplastic syndrome and acute myeloid leukemia].
Kojima K
Rinsho Ketsueki; 2023; 64(9):955-961. PubMed ID: 37793871
[TBL] [Abstract][Full Text] [Related]
7. Overview: A New Era of Cancer Genome in Myeloid Malignancies.
Kiyoi H
Oncology; 2015; 89 Suppl 1():1-3. PubMed ID: 26551625
[TBL] [Abstract][Full Text] [Related]
8. The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia.
Gonzalez-Lugo JD; Chakraborty S; Verma A; Shastri A
Semin Hematol; 2021 Jan; 58(1):56-65. PubMed ID: 33509444
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting of the inflammasome in myeloid malignancies.
Chakraborty S; Shapiro LC; de Oliveira S; Rivera-Pena B; Verma A; Shastri A
Blood Cancer J; 2021 Sep; 11(9):152. PubMed ID: 34521810
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
11. Vorinostat induces apoptosis and differentiation in myeloid malignancies: genetic and molecular mechanisms.
Silva G; Cardoso BA; Belo H; Almeida AM
PLoS One; 2013; 8(1):e53766. PubMed ID: 23320102
[TBL] [Abstract][Full Text] [Related]
12. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
13. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
Fischer T; Stone RM; Deangelo DJ; Galinsky I; Estey E; Lanza C; Fox E; Ehninger G; Feldman EJ; Schiller GJ; Klimek VM; Nimer SD; Gilliland DG; Dutreix C; Huntsman-Labed A; Virkus J; Giles FJ
J Clin Oncol; 2010 Oct; 28(28):4339-45. PubMed ID: 20733134
[TBL] [Abstract][Full Text] [Related]
14. [Research progress on mechanism of MDS transformation into AML].
Wang LL; Gao C; Chen BA
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):254-9. PubMed ID: 21362264
[TBL] [Abstract][Full Text] [Related]
15. Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines.
Hu XM; Yuan B; Tanaka S; Song MM; Onda K; Tohyama K; Zhou AX; Toyoda H; Hirano T
Hematology; 2014 Sep; 19(6):352-60. PubMed ID: 24192507
[TBL] [Abstract][Full Text] [Related]
16. Role of lenalidomide in the treatment of myelodysplastic syndromes.
Komrokji RS; List AF
Semin Oncol; 2011 Oct; 38(5):648-57. PubMed ID: 21943671
[TBL] [Abstract][Full Text] [Related]
17. The emerging role of immune checkpoint based approaches in AML and MDS.
Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies.
Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Zhang W; Yang L; Yan Y; Lin J; Qian J
J Cell Mol Med; 2017 Aug; 21(8):1468-1481. PubMed ID: 28452111
[TBL] [Abstract][Full Text] [Related]
19. Do preclinical studies suggest that CD99 is a potential therapeutic target in acute myeloid leukemia and the myelodysplastic syndromes?
Tavakkoli M; Chung SS; Park CY
Expert Opin Ther Targets; 2018 May; 22(5):381-383. PubMed ID: 29637789
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic therapies in MDS and AML.
Griffiths EA; Gore SD
Adv Exp Med Biol; 2013; 754():253-83. PubMed ID: 22956506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]